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Purpose: Validation of dose escalation through FDG-PET dose painting (DP) for oropharyngeal squamous cell
carcinoma (SCC) requires randomized clinical trials with large sample size, potentially involving different treatment
planning and delivery systems. As a first step of a joint clinical study of DP, a planning comparison was performed
between Tomotherapy HiArt® (HT) and Varian RapidArc® (RA).
Methods: The planning study was conducted on five patients with oropharyngeal SCC. Elective and therapeutic
CTVs were delineated based on anatomic information, and the respective PTVs (CTVs + 4 mm) were prescribed a
dose of 56 (PTV56) and 70 Gy (PTV70). A gradient-based method was used to delineate automatically the external
contours of the FDG-PET volume (GTVPET). Variation of the FDG uptake within the GTVPET was linearly converted
into a prescription between 70 and 86 Gy. A dilation of the voxel-by-voxel prescription of 2.5 mm was applied to
account for geometric errors in dose delivery (PTVPET). The study was divided in two planning phases aiming at
maximizing target coverage (phase I) and lowering doses to OAR (phase II). A Quality-Volume Histogram (QVH)
assessed conformity with the DP prescription inside the PTVPET.
Results: In phase I, for both HT and RA, all plans achieved comparable target coverage for PTV56 and PTV70,
respecting the planning objectives. A median value of 99.9 and 97.2% of all voxels in the PTVPET received at least
95% of the prescribed dose for RA and HT, respectively. A median value of 0.0% and 3.7% of the voxels in the
PTVPET received 105% or more of prescribed dose for RA and HT, respectively. In phase II, no significant differences
were found in OAR sparing. Median treatment times were 13.7 min for HT and 5 min for RA.
Conclusions: Both HT and RA can generate similar dose distributions for FDG-PET based dose escalation and dose
painting in oropharyngeal SCC patients.* Correspondence: vincent.gregoire@uclouvain.be
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After concomitant chemo-radiotherapy for locally advanced
squamous cell carcinoma of the head and neck (HNSCC),
still 20 to 30% of patients suffer from loco-regional recur-
rences, typically within the gross tumor volume (GTV) [1],
motivating local dose escalation. Over the last decade, the
introduction of intensity modulated radiation therapy
(IMRT) creating larger dose gradients between target
volumes and the surrounding normal tissues has opened an
avenue for radiation dose escalation. However, the dose can
only be increased to some extent; indeed increased late tox-
icity has been observed with increased dose prescription
[2]. This observation led to the concept of image-driven
dose painting, where the dose is prescribed, delivered and
possibly increased non uniformly within target volumes
based on maps of detrimental biological factors such as
tumor hypoxia, tumor metabolism, cell proliferation [3–6].
In dose painting by numbers (DPBN), the dose is
prescribed and possibly escalated as a function of the voxel
intensity of a given molecular imaging modality [3].
Clinical validation of a DPBN strategy requires the
conduction of randomized clinical trials with a large
number of patients treated in several centers with most
likely different treatment planning and delivery systems.
According to the website “clinicaltrial.gov”, there are at the
time of writing four ongoing randomized phase II trials
about dose escalation in HNSCC patients. But while
most protocols are based on a uniform dose escalation
inside a predefined volume (ClinicalTrials.gov identifier:
NCT01212354, NCT02352792, NCT02089204) only one
study is recruiting at present for a non uniform dose
escalation based on DPBN (Ghent University Hospital in
Belgium, ClinicalTrials.gov identifier: NCT01341535). This
study uses in-house treatment planning systems (TPS), and
its methodology may not be straightforward to transpose in
commercial TPS.
Over the last few years, the feasibility of generating DPBN
plans with commercial TPS e.g. Helical TomoTherapy
(HT) and Varian RapidArc (RA) has also been demon-
strated, and several planning studies have been conducted
on HNSCC cases [7–9]. However, there is no head-to-head
comparison of the capabilities of both solutions in the con-
text of dose escalation based on FDG-PET DPBN, where a
very precise voxel-by-voxel dose distribution has to be ob-
tained. Hence, the question arises whether both treatment
systems can achieve similar performance and thus be used
within the same clinical trial of DPBN.
As a first step on the way towards a joint clinical trial,
this study carries out a dosimetric comparison of dose
painting plans with a dose escalation from 70 to 86 Gy
inside the GTV delineated in FDG-PET images. The aim
was to evaluate the capabilities of both HT and RA sys-
tems to plan and deliver accurately a given complex
non-uniform dose prescription, and to challenge bothsystems in extreme clinical configurations. Dose hetero-
geneity pushes treatment-planning systems to their
limits because steep and controlled dose gradients are
needed.
Material and methods
Patient selection and image acquisition
Five patients with stage IV (TNM 2007) oropharyngeal
SCC treated with concomitant chemo- or cetuximab-
radiotherapy were selected. All patients had a minimal
tumor diameter of 3 cm. Information about the exact
tumor location, the staging and the tumor volume are
presented in the Additional file 1.
Patients underwent a contrast-enhanced CT and 18F-
FDG-PET on a combined PET/CT camera (Gemini TF,
Philips Medical system, Cleveland, OH, USA). Contrast-
enhanced CT scans were performed using a slice thick-
ness of 2 mm, a reconstruction interval of 2 mm and a
pitch of 0.8. Axial images were reconstructed using a
matrix of 512 × 512 pixels with a size of 0.52 × 0.52 ×
1 mm3. The three-dimensional PET images were acquired
with an axial field of view of 155 mm (two bed positions
centered on the primary tumor), a matrix of 288 ×
288 pixels with a size of 2 × 2 × 2 mm3. Acquisitions were
performed 90 min after the injection of 281–304 MBq of
18F-FDG. The PET images were reconstructed with the 3D
line of response, time-of-flight (TOF) blob-based ordered
subset expectation maximization (OSEM) algorithm from
Philips with 3 iterations and 33 subsets [10]. The resolution
of the PET images measured in the center of the field of
view (FOV) with a point source in attenuating material led
to a full width at half maximum (FWHM) of 6.5 mm.
More details about image acquisition and segmentation
have already been published [8].
Target volume, Organ at Risk and dose-volume
constraints
Delineation of the PET-based target volumes
A gradient-based method was used to delineate auto-
matically the external contours of the primary tumor
FDG-PET GTV (GTVPET) [11]. Quantitative conversion
of the PET signal into a heterogeneous dose prescription
from 70 Gy to 86 Gy was performed using a linear rela-
tionship between the median and maximal 18F-FDG up-
take values in the GTVPET. Robustness against
geometrical uncertainties was ensured with the method-
ology introduced by Sterpin et al. [12]. The PTVPET,
which was used for dose prescription, was obtained
accordingly by dilating the voxel-by-voxel prescription
for the GTVPET by 2.5 mm to account for systematic er-
rors, while random errors could be neglected. In order
to guide the optimizer to approach the voxel-by-voxel
prescription, seven equidistant sub-levels were defined
inside the PTVPET allowing grouping the voxels into
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corresponding to a percentage of the maximum FDG
uptake into the PTVPET was then converted into a dose
prescription, as a percentage of the maximal dose incre-
ment of 16 Gy. This threshold value was set to the min-
imal dose constraint in the TPS. As the FDG uptake
voxel distribution within each sub-level is known to be
heterogeneous, the maximum dose constraint for the ith
level equaled the minimum dose constraint of level i + 1.
Clinical target volumes and Organ At Risk
Clinical target volumes (CTV) and the nearby organs at
risk (OAR) were delineated on the planning CT using
the CMS® treatment planning software (Elekta Comput-
erized Medical System, version 4.64.00, Stockholm,
Sweden) as already described [8]. In short, the so-called
therapeutic CTV70 (i.e. the CTV with a dose prescription
of 70 Gy) was defined as the GTV delineated in the plan-
ning CT + 5 mm (both for the primary tumor and for the
lymph node metastases), taking into account that bone,
cartilages, ligaments and muscles prevent tumor spread.
The so-called prophylactic CTV for both the primary
tumor (normal tissue at risk of tumor spread surrounding
the GTV) and the bilateral elective lymph node areas
(delineated according to Grégoire et al. [13, 14]) were
united to create the CTV56 (i.e. the CTV with a dose pre-
scription of 56 Gy). Last, the PTV70 and PTV56 were
drawn by expanding the CTVs with an isotropic 4 mm
margin [15]. A volume defined as a 3 mm thick layer
within the patient body contour was excluded from the
PTV to avoid skin overdosage. The following OARs were
contoured: spinal cord, brainstem, parotid glands, oral
cavity, larynx, lower pharyngeal constrictor muscle
(PCM), cricopharyngeal muscle, cervical esophagus and
mandible. OARs lying (almost) completely within theTable 1 Dose-volume constraints for the PTV and OAR





PTV56 56 - ≥90%
PTV70 70 - ≥90%
PRV spinal cord - -
PRV brainstem - -
Contralateral parotid gland - ≤26 -
Ipsilateral parotid gland - ≤30 -
Oral cavity - ≤30 -
Larynx - ≤40 -
Lower PCM - ≤50 -
Cricopharyngeal muscle - ≤50 -
Cervical esophagus - ≤35 -
Mandible - - -
PCM pharyngeal constrictor musclePTV (i.e. submandibular glands, superior and middle
PCM) were not contoured. A planning at risk volume
(PRV) was created by adding a 4 mm margin around the
spinal cord and the brainstem.
Dose-volume constraints
As aforementioned, the PTVPET dose prescription varied
linearly with the FDG uptake, from its median value to
its maximum. The additional dose volume constraints
used are presented in Table 1.
Design of the planning study
The study was divided into two phases. The first phase
aimed at evaluating the ability of both planning and de-
livery systems to conform the treatment plans to a het-
erogeneous dose prescription using a set of pre-defined
constraints to the OAR. The focus was set on the PTV
coverage. To allow the maximum degrees of freedom for
target coverage, only four OARs were considered (i.e. ip-
silateral and contralateral parotid glands, PRV spinal
cord and PRV brainstem). The second phase aimed at
evaluating the ability of both systems to plan the heteroge-
neous dose escalation of 16 Gy inside the PTVPET while
lowering the dose to the OARs as much as possible. In
this two-step procedure, coverage of the PTVPET could be
analyzed before and after possible degradation caused by
the dose decrease to OARs.
In each institution, only one operator performed the
treatment planning for all patients (SD for HT and NH
for RA) under the supervision of a senior physicist. To
ensure a fair comparison, for each case, the operators
were given the possibility to further improve the plan
quality by evaluating what was achieved by the other
technique. All plans were considered final after a second
round of plan modification and no additional changer-min (D98%) (Gy) D95% Dnear-max (D2%) (Gy)
of prescribed dose ≥95% of prescribed dose -
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was checked by two head-and-neck radiation oncologists
(VG and SN). The plans were transferred to the com-
mercial software MIM 6.1. (MIMVista corp, Cleveland,




For HT, treatment planning was performed on a Tomother-
apy research planning station version 136.1111.0 with a
GPU architecture, with accuracy comparable to the exten-
sively validated CPU algorithm [17, 18]. Based on previous
planning optimization, longitudinal field width of 1.05 cm,
a maximum modulation factor of 3 and a pitch of 0.215–
0.43 were used. These parameters showed to be optimal for
DP plans with HT in a previous publication [8]. The dose
calculation was performed with the collapsed-cone-
convolution algorithm and a grid size set to ‘fine’, which
typically corresponds to a 2 × 2 mm2 resolution in the
transverse plane.
RapidArc plans
RA plans were generated for a Varian CLINAC 2100 C/D
equipped with the 120-leaf Millennium Multileaf Collima-
tor system, with forty 5-mm central leaf-pairs and twenty
10-mm peripheral leaf-pairs. The plans were optimized
using the Progressive Resolution Optimizer (PRO)
10.0.28. After optimization, the final dose distribution was
calculated using the Anisotropic Analytical Algorithm
(AAA 10.0.28) with a grid size of 1.5 × 1.5 mm2.
Optimal plans were obtained for a 6-MV beam and 4 full
arcs with collimator rotation of 5°–15° and 75°–85°. The
isocenter was centered on the volume of the highest dose
prescription. The contribution of each arc to the PTVPET
was assured by a minimal jaws opening of 2 cm over the
isocenter and a X-jaws opening up to 15 cm, i.r. the max-
imal leaf-traveling per bank. Collimator angles differed of at
least 10° to increase the degree of freedom of the optimizer
while remaining close to the typical in-house standard of 2
full arcs with collimator rotation of 10° and 80°. Modulation
was pushed to about 280 MU/arc.
Both dose calculation algorithms use conventional
“rescaled-to-water” calculation.
Plan evaluation
Plans were evaluated qualitatively by visual inspection of
the dose distribution on each axial CT slice, and quanti-
tatively from the Dose Volume Histograms (DVH) and
the Quality Volume Histograms (QVH). For all PTVs
but the painted volume, D50% (median dose), D95%, D98%
(near-minimal dose) and D2% (near-maximal dose) were
chosen. Homogeneity of the dose distribution was calcu-
lated with the homogeneity index as described in theICRU 83 report [19]. The degree of conformity of the
plans was evaluated through the conformity index,
CI95%, i.e. the ratio between the patient volume receiving
at least 95% of the prescribed dose and the volume of
the PTV.
QVHs were used to assess the dose conformity with the
non-uniform dose prescription inside the PTVPET, as pro-
posed by Vanderstraeten et al. [20]. The Q-value is the ra-
tio between the planned dose and the prescribed dose at
each dose voxel inside the dose-painted volume i.e.
PTVPET. Vanderstraeten et al. [20] also introduced the
quality factor (QF) given by ∑i=1…N |1 - Qi|/N, where N is
the total number of dose points at which Q-values are cal-
culated. Planning objectives were then set as follows:
VQ=0.95 ≥ 95%, VQ=1.05 ≤ 5% and QF ≤ 5% [20, 21]. For
QVH calculation, an in-house research platform was used.
Beam-on-times were directly given by the TPS in HT
while for RA they were calculated in RT Chart, ARIA
(Varian Medical Systems, Palo Alto, CA, USA).Quality assurance on the dose delivery (DQA)
DQA on the dose delivery was performed on patient #3.
For HT, as mentioned above, treatment planning was per-
formed on a research version of the Tomotherapy TPS.
The latter not being connected to the clinical treatment
station, DQA could not be performed. In order to bypass
this limitation, a new plan meeting the planning con-
straints of phase II was calculated on the clinical treat-
ment planning station version 5.1.0.4 for patient #3. The
treatment plans were delivered on a Tomotherapy HD®.
For both RA and HT, the dose distribution verifica-
tion consisted of a film measurement (EBT-3 type Gaf-
chromic® films) as well as point dose measurements
made with ion chambers (A1SL Exradin miniature
Shonka thimble type chamber, Standard Imaging, Inc.,
Middleton, WI). For RA, these measurements were per-
formed in the arcCHECK phantom (Sun Nuclear Corp,
Melbourne FL) used as a simple cylindric phantom
[22]. For HT, these measurements were performed in a
specially designed solid-water phantom called the
cheese phantom [23].
The agreement between the calculated and the mea-
sured film dose distributions was evaluated with a global
gamma index. Three % / 3 mm was selected as accept-
ance criteria in the gamma analysis.Statistical analysis
Differences in parameters of interest between treatment
planning systems were analyzed with the Wilcoxon
signed-rank test (SPSS statistical package; version 17.0;
SPSS Inc.; Chicago, IL) and p-values lower than 0.05
were considered statistically significant.
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As an example, comparative isodose distribution on axial
slices between HT and RA is presented for patient #5
(Fig. 1). The corresponding DVH for PTVs and OARs
are displayed in Fig. 2. Similar figures for the 4 other
patients are presented in the Additional file 2.
Tables 2 and 3 summarize the quantitative data analysis
for PTV and OARs for planning phases I and II, respect-
ively. For planning phase I, the focus was set on the ability
of both systems to reach adequate PTV coverage and
QVH values. For all patients, the clinical requirements for
PTV coverage and OARs sparing are met for both HT and
RA. PTV70 and PTV56 show similar results except for D2%
of PTV70 and PTV56, and for D50% of PTV56 that are all
statistically significantly smaller for HT. Moreover, HT
achieves higher conformity for PTV56. No differences are
seen on dose homogeneity between HT and RA.
Regarding QVH values, QF stays below 2% for both
modalities in all patients but patient #5. For this patient’s
HT plan, VQ=0.95 reaches 92.7% and VQ=1.05 reaches
4.9%, while the QF raises up to 2.3% (Fig. 3). Globally,
mean QVH values are statistically significantly better for
RA than HT. Similar QVHs for the four other patients
are provided in Additional file 3. Last, regarding treat-
ment times, median treatment times are 13.7 min for
HT and 5 min for RA. Total planning times are esti-
mated to be around 2–3 h for TomoTherapy and aroundFig. 1 PTV and isodose distribution (planning phase II) for Helical Tomothe
zooms of the PTVPET. Only PET levels 1,3,5 and 7 are depicted to improve t3–4 h for RapidArc to obtain a dose distribution achiev-
ing all planning objectives. If the total time gives advan-
tage to HT, it has to be mentioned that the interaction
time between the user and the TPS is shorter with RA,
the longest step for each iteration being the final dose
calculation where the user doesn’t need to interact with
the TPS any longer.
For planning phase II, the constraints are achieved for
all OARs with both HT and RA except for the larynx and
the oral cavity due to close proximity of the PTV. When
this was the case, the dose was lowered as much as pos-
sible in the part of the organ outside of the PTV plus a
5 mm-wide region. Regarding PTV coverage, both HT and
RA met the constraints with subtle differences between
the two systems, few of them reaching statistical signifi-
cance, but not clinical significance. Regarding the QVH
analysis, similar conclusions as for phase I can be drawn.
Systematic differences favoring RA were observed.
Last, regarding the QA, a good agreement between the
planned and delivered dose distribution was found in pa-
tient #3 with gamma pass rates above 96% for the 3%/
3 mm criteria for both HT and RA (Additional file 4).
Discussion
In summary, our study shows that providing the systems
are pushed to their upmost limit and cross-checked, both
HT and RA can produce similar dose distributions inrapy (HT) and Varian RapidArc (RA) for patient #5. The captions are
he visualization
Fig. 2 Dose-Volume Histogram (DVH) for the Planning Target Volume (PTV) and the Organ At Risk volume (OAR) for patient #5 in planning phase
II. The DVH for the PTVs are represented in a non-overlapping mode. The plain lines are for RapidArc and the dashed lines are for Helical
Tomotherapy. (BS: brainstem; SC: spinal cord)
Differding et al. Radiation Oncology  (2017) 12:59 Page 6 of 10patients with SCC of the oropharynx using FDG-PET dose
painting for dose escalation. The various metrics used for
plan comparison were nearly identical; when differences
were noticed between the two techniques, they did not
reach any level of clinical significance. By “pushed to their
upmost limit and cross-checked”, we meant that the
objective of our study was not so to identify a “winner” in
this planning exercise, but rather to demonstrate that two
planning and delivery systems can achieve similar dose
distribution in the framework of dose painting for dose
escalation, providing adequate settings of the two systems
are used. However, this is an initial assessment based on a
small sample size and it would be interesting to expand it
to a larger number of patients.
To our knowledge, this study presents the first com-
parison between two rotational IMRT techniques, in the
context of dose escalation based on FDG-PET dose
painting. HT has already been compared to step-and-
shoot IMRT for dose escalation and dose painting plans
[24]. A higher degree of conformity was observed with
the inhomogeneous dose prescription with HT than with
nine fields step-and-shoot IMRT, although the authors
concluded that both modalities were clinically suitable
for dose painting. On the other hand, several studies
comparing rotational IMRT systems without dose escal-
ation in patients with HNSCC have been reported in the
literature [25–30]. Most of them found significantly
higher normal tissue dose sparing with HT than with
RA [25, 28–30]. Regarding target coverage, Stromberger
et al. reported only small differences comparing both
modalities for unilateral and bilateral simultaneous
integrated boost plans [28]. Our study revealed that
both rotational techniques generate relatively similar
dose distribution regarding both PTV coverage and
OAR sparing. However, one should mention that toobtain such conformed plans with RA, we had to
use more arcs than what is routinely used in the
clinics. The use of four independent arcs that were
simultaneously optimized might have allowed the
RA’s optimizer to achieve higher target coverage and
OAR sparing than in studies where only one or two
arcs were used, especially when it turned to compute
heterogeneous dose prescriptions such as in dose
painting. Such finding has also been reported by
Martin et al. who found a significant improvement
in plan quality with the use of additional arcs [16].
In terms of conformity, HT achieved a better CI for
PTV56 than RA. This is consistent with the study of
Wiezorek, while Van Gestel et al. reported a better
CI for the RA modality [29, 30]. Our results showed
that homogeneity in PTV70 was higher with HT,
confirming results of previous studies [25, 29, 30].
But it should be mentioned that, although statisti-
cally significant, such small differences between HT
and RA did not reach any significance from a clin-
ical point of view, i.e. that no clinical advantage is
expected both from a toxicity or a local tumor con-
trol point of view.
The design of a comparative study between different
planning and delivery systems impacts on the final re-
sults. In our study, each operator had the opportunity
to further improve plan quality in a second round
after a first comparison was done. The main advan-
tage of such strategy is that we ensure that the phys-
ical capabilities of the systems are tested to their
limits. However, it does not give information about
how would perform an experienced planner on a par-
ticular system without having any knowledge of the
capabilities of the other system. This chance for a “re-
buttal” plan has been found only in one comparison
Table 2 Comparison between various metrics in planning phase I. The data are the median and range values of the five patients
included into the study. PTV70+PET corresponds to the PTV70 encompassing the PTVPET, while PTV70 is the part of the PTV70 outside of
the PTVPET. In a similar way, PTV56 is the part of the PTV56 outside of the PTV70
PHASE I RapidArc Helical Tomotherapy p-value
Median Min - Max Median Min - Max
QVH indexes VQ=0.95 (%) 99.9 98.7–100.0 97.2 92.7–97.6 0.043
VQ=1.05 (%) 0.0 0.0–0.2 3.7 2.0–4.9 0.043
QF (%) 1.4 1.2–1.8 1.9 1.8–2.3 0.043
PTV70+PET D98% (Gy) 67.3 67.0–67.8 67.4 66.7–67.8 n.s.
D95% (Gy) 68.0 67.7–68.4 68.3 67.5–68.5 n.s.
D50% (Gy) 70.1 70.0–70.4 70.1 69.8–70.3 n.s.
D2% (Gy) 79.1 74.9–81.3 79.4 76.3–82.2 n.s.
V95% (%) 99.4 99.1–99.8 99.4 98.3–99.8 n.s.
HI 0.2 0.1–0.2 0.2 0.1–0.2 n.s.
PTV70 D98% (Gy) 67.2 66.9–67.8 67.2 66.6–67.7 n.s
D95% (Gy) 67.9 67.5–68.3 68.1 67.4–68.4 n.s
D50% (Gy) 69.9 69.8–70.4 70.0 69.7–70.3 n.s
D2% (Gy) 72.1 72.0–72.5 71.5 70.8–72.0 0.043
V95% (%) 99.3 98.9–99.8 99.3 98.1–99.8 n.s
V107% (%) 0.0 0.0–0.0 0.0 0.0–0.1 n.s
HI 0.1 0.1–0.1 0.1 0.0–0.1 n.s
PTV56 D98% (Gy) 54.1 53.9–54.6 54.6 53.9–54.9 n.s.
D95% (Gy) 54.6 54.4–54.9 55.0 54.3–55.2 n.s.
D50% (Gy) 56.6 56.4–57.0 55.9 55.8–56.2 0.043
D2% (Gy) 68.2 67.4–68.5 68.0 65.9–68.2 0.043
V95% (%) 99.6 99.2–99.9 99.8 99.5–99.9 n.s.
V107% (%) 13.8 11.7–21.7 11.5 9.8–20.3 n.s.
HI 0.2 0.2–0.3 0.2 0.2–0.3 n.s.
PRV SC D2% (Gy) 47.6 47.1–47.8 47.2 43.0–47.6 -
a
PRV BS D2% (Gy) 39.2 34.0–47.2 35.8 25.4–43.4 -
a
Ipsilateral parotid Dmean (Gy) 28.8 28.5–29.5 28.7 27.1–29.8 -
a
Contralateral parotid Dmean (Gy) 24.8 23.9–25.1 22.9 21.3–25.2 -
a
Conformity Index CI PTV70 1.2 1.2–1.2 1.2 1.1–1.2 n.s.
CI PTV56 1.7 1.6–2.0 1.5 1.4–1.8 0.043
ano Wilcoxon signed-rank test performed as the dose to OAR had to reach the constraint but was not further optimized in planning phase I
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point varies between different comparison studies. Most
of them take a dataset of previously treated patients and
perform a new optimization for each evaluated technique
[25–30]. In other studies, however, the delivered treatment
plan is taken as reference and a new plan is retrospectively
optimized for the other techniques [32, 33]. It remains
then questionable how far the initial plans were optimized
in comparison to the new plans generated in the frame of
a study. Last, the two phases design of our study with a
first phase aiming at maximal target coverage with soft
OAR constraints and a second one aiming at maximal
OAR sparing brings more clarity in the results.The total planning time was estimated between 2 and
4 h for both planning systems. This is obviously more
than what is typically required for a routine homoge-
neous dose distribution in HNSCC. It should be noticed
that HT and RA planning was done by two different
operators, who both had to learn how to achieve the
best dose distribution for such complex plans. Compari-
son between the 2 systems is thus difficult, but it looks
like a more satisfactory dose distribution was achieved
quicker with HT than with RA.
Of special interest to us is the comparison between
HT and RA for the non-uniform dose planning. Al-
though both systems were able to achieve clinically
Table 3 Comparison between various metrics in planning phase II. The data are the median and range values of the five patients
included into the study. PTV70+PET corresponds to the PTV70 encompassing the PTVPET while PTV70 is the part of the PTV70 outside of
the PTVPET. In a similar way, PTV56 is the part of the PTV56 outside of the PTV70
PHASE II RapidArc Helical Tomotherapy p-value
Median Min - Max Median Min - Max
QVH indexes VQ=0.95 (%) 99.7 99.4–100.0 95.3 92.2–96.4 0.043
VQ=1.05 (%) 0.2 0.0–0.4 2.6 0.7–6.5 0.043
QF (%) 1.5 1.3–1.6 1.9 1.8–2.3 0.043
PTV70+PET D98% (Gy) 66.4 65.7–67.0 66.6 66.0–67.0 n.s.
D95% (Gy) 67.3 66.8–67.9 67.6 67.0–67.7 n.s.
D50% (Gy) 70.3 70.1–70.5 70.0 69.9–70.3 0.043
D2% (Gy) 79.7 75.2–81.7 79.6 75.6–81.7 n.s.
V95% (%) 97.8 96.2–98.8 98.1 96.8–99.0 n.s.
HI 0.2 0.1–0.2 0.2 0.1–0.2 n.s.
PTV70 D98% (Gy) 66.3 65.6–66.5 66.4 65.9–66.7 n.s.
D95% (Gy) 67.2 66.6–67.5 67.3 66.9–67.5 n.s.
D50% (Gy) 70.1 69.8–70.3 69.9 69.8–70.1 0.042
D2% (Gy) 73.0 72.7–73.4 71.6 71.3–71.9 0.043
V95% (%) 97.6 95.4–98.0 97.7 96.4–98.5 n.s.
V107% (%) 0.0 0.0–0.1 0.0 0.0–0.0 n.s.
HI 0.1 0.1–0.1 0.1 0.1–0.1 0.039
PTV56 D98% (Gy) 53.6 53.2–53.8 53.9 51.6–54.3 n.s.
D95% (Gy) 54.4 54.1–54.5 54.6 53.6–54.9 n.s.
D50% (Gy) 56.7 56.5–57.2 55.9 55.7–56.2 0.043
D2% (Gy) 67.5 67.0–68.1 65.8 65.7–67.2 0.042
V95% (%) 98.7 98.0–99.2 99.0 96.1–99.2 n.s.
V107% (%) 12.0 10.1–20.7 11.0 8.6–14.2 0.043
HI 0.2 0.2–0.3 0.2 0.2–0.3 n.s.
PRV SC D2% (Gy) 27.8 24.5–29.9 26.4 24.8–28.5 n.s.
PRV BS D2% (Gy) 22.5 17.2–24.4 21.3 17.9–23.7 n.s.
Ipsilateral parotid Dmean (Gy) 26.6 24.8–28.9 26.8 25.0–28.3 n.s.
Contralateral parotid Dmean (Gy) 21.6 19.2–23.9 21.0 20.4–24.7 n.s.
Oral cavity Dmean (Gy) 28.5 19.4–42.0 28.2 18.1–44.4 n.s.
Oral cavity minus PTV Dmean (Gy) 18.3 16.6–22.3 19.8 15.8–27.0 n.s.
Lower PCM Dmean (Gy) 38.2 26.0–47.7 37.5 24.0–50.9 n.s.
Cricophar. muscle Dmean (Gy) 23.6 14.9–35.2 22.5 13.8–34.7 n.s.
Cervical esophagus Dmean (Gy) 15.1 12.6–19.7 14.2 10.0–21.4 n.s.
Larynx Dmean (Gy) 46.1 29.3–54.0 49.6 24.2–54.7 n.s.
Larynx minus PTV Dmean (Gy) 21.6 17.3–30.5 23.2 17.3–28.8 n.s.
Mandible D5% (Gy) 58.5 57.0–65.5 59.2 55.8–68.5 n.s.
Conformity index CI PTV70 1.1 1.0–1.1 1.1 1.0–1.1 n.s.
CI PTV56 1.3 1.3–1.5 1.3 1.2–1.4 n.s.
PCM pharyngeal constrictor muscle
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served for RA. Intrinsic differences between both
TPS regarding the optimization process and the leaf
sequencing could be a possible explanation to thisobservation. In particular, RA simulations were per-
formed with a MLC with 120 leaves (5 mm leaf ’s
width), which resulted in a higher longitudinal reso-
lution than with the HT collimator, which has a
Fig. 3 Quality Volume Histogram (QVH) for the PTVPET for patient #5
in planning phase I
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dinal direction, the resolution of HT will conse-
quently be limited by the jaw width whereas the
resolution of the RA collimator is limited only by
the width of the leaves. This could limit the capabil-
ity of HT of creating very high modulation’s degree.
In addition, resolution differences between the TPS
of Tomotherapy and Varian could also be respon-
sible for differences in QVH quality. Sub-levels in-
side the PTVPET are very small and close to each
other. A small difference in contour modeling and/
or in the interpolation of dose grid data to sample
points in these tiny volumes could account for dif-
ferences in the calculated dose at the voxel level.
Furthermore, the QF calculation in itself suffers from
the important limitation that values will always be
heavily weighted to the DP sub-volumes with small
dose increment, due to the larger number of voxels
within these larger, peripheral regions.
In these technically complex dose painting plans,
as already reported by others in HNSCC patients,
delivery with RA clearly proves to be faster than
with HT, even though four arcs were used [29, 30].
This is explained by the fact that HT plans had to
be performed all the way through with a jaw width
of 1.05 cm to allow high conformity in the longitu-
dinal axis, leading to a significant increase in treat-
ment times. An ideal workaround would involve the
ability to vary the jaw width of the HT collimator
and the speed of the couch movement when it
comes to irradiate parts of the PTV that do not re-
quire high modulation. Unfortunately, such option isnot available in the HT system. Treatment time re-
mains important not only for the patient’s comfort
but also because of possible intra-fraction motion of
the tumor. Such phenomenon is, however, negligible
in oropharyngeal SCC [34].
Last, in this study, the comparison between RA and
HT was also performed from a delivery point of view in
one patient, and it showed that DPBN plans could be
successfully delivered by both techniques.
Conclusion
In summary, all plans in both groups achieved ac-
ceptable target coverage for all included volumes, re-
specting the planning objectives except for one
patient where all QVH objectives could not be met
with HT. Such a comparison was necessary to en-
sure that patients treated with both systems can be
accrued in the same multicentric clinical studies. In
this context, a phase-I study (ClinicalTrials.gov
identifier: NCT02336711) on FDG-PET based dose
escalation and dose painting has recently started at
the UCL Cliniques universitaires St-Luc and KUL
Gasthuisberg universitair ziekenhuis, equipped with
HT and RA, respectively.
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